title: Messenger ribonucleic acid expression of 16 matrix metalloproteinases in bone-implant interface tissues of loose artificial hip joints.
abstract: Matrix metalloproteinases (MMPs) have been reported to be the major factors responsible for aseptic loosening of artificial hip joints. So far, messenger ribonucleic acid (mRNA) expression patterns of seven MMPs have been reported, but that of many other MMPs which have been newly discovered or recently considered to be responsible for prosthetic loosening is still unknown. In this study, mRNA expression pattern of 16 different types of MMPs were analyzed to evaluate which MMPs were locally produced and contributed to prosthetic loosening. Synovium-like interface tissues between bone and prosthesis were collected from 18 cases of aseptic loose artificial hip joint at revision surgery. Six cases of normal synovium were used as controls. Total RNA was extracted by single-step acid guanidinium-thiocyanate-phenol-chloroform procedure. mRNA expression of MMPs was analyzed by semiquantitative reverse transcription-polymerase chain reaction. Based on local expression pattern of MMPs at the mRNA level, aseptic loose artificial hip joint was characterized by elevated expression of MMP-1, MMP-9, MMP-10, MMP-12, and MMP-13; moderate expression of MMP-2, MMP-7, MMP-8, MMP-11, membrane type (MT)1-MMP (MMP-14), MT2-MMP (MMP-15), MT3-MMP (MMP-16), MT4-MMP (MMP-17), and MMP-19; lower expression of MMP-3; and little significance of MMP-20. The MMPs detected in this study can potentially degrade almost all components of the periprosthetic extracellular matrix. Thus, many MMP type enzymes possibly contribute to prosthetic loosening and osteolysis through pathologic extracellular matrix degradation and connective tissue/bone remodeling around prostheses.
authors.affiliation: Department of Orthopedic Surgery, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan. isaotake@hospital.sakata.yamogata.jp
authors.forename: I
authors.initials: I
authors.lastname: Takei
authors.forename: M
authors.initials: M
authors.lastname: Takagi
authors.forename: S
authors.initials: S
authors.lastname: Santavirta
authors.forename: H
authors.initials: H
authors.lastname: Ida
authors.forename: M
authors.initials: M
authors.lastname: Ishii
authors.forename: T
authors.initials: T
authors.lastname: Ogino
authors.forename: M
authors.initials: M
authors.lastname: Ainola
authors.forename: Y T
authors.initials: YT
authors.lastname: Konttinen
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001843:Bone Cements; D016723:Bone Remodeling / Q000235:genetics; D004790:Enzyme Induction; D005109:Extracellular Matrix / Q000201:enzymology / Q000378:metabolism*; D016326:Extracellular Matrix Proteins / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling; D006621:Hip Joint / Q000378:metabolism*; D006622:Hip Prosthesis; D006801:Humans; D008297:Male; D019278:Matrix Metalloproteinase 3; D020782:Matrix Metalloproteinases / Q000096:biosynthesis / Q000235:genetics*; D008875:Middle Aged; D016348:Osseointegration / Q000235:genetics*; D011475:Prosthesis Failure; D012333:RNA, Messenger / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D001843:Bone Cements; D016326:Extracellular Matrix Proteins; D012333:RNA, Messenger; D020782:Matrix Metalloproteinases; D019278:Matrix Metalloproteinase 3